VVS = vasovagal syncope, CSS = carotid sinus syncope, ppm = pacemaker
Summary of major open-label and observational studies for pacing in vasovagal syncope
Open access peer-reviewed chapter
By Vikas Kuriachan and Robert Sheldon
Submitted: November 23rd 2010Reviewed: May 18th 2011Published: September 15th 2011
Neurally mediated syncope syndromes involve autonomic reflexes causing bradycardia and/or hypotension resulting in a transient loss of consciousness(Brignole et al., 2004). These episodes can result in injuries and emotional stress. Recurrent vasovagal syncope can have a significant detrimental effect on the quality of life comparable to chronic disease patients with chronic back pain or rheumatoid arthritis(Linzer et al., 1991; Rose, Koshman, Spreng, & Sheldon, 2000). Hence management strategies have targeted vasodepression and bradycardia. Pacing has been a tempting solution that treats the cardioinhibitory response.
Vasovagal syncope is one of the common causes of syncope and a common reason for emergency room encounters(Savage, Corwin, McGee, Kannel, & Wolf, 1985). Vasovagal syncope is seen in younger patients and the reflex may have triggers such as sight of blood, venipuncture, or prolonged standing(Brignole et al., 2004). Some patients may have a prodrome of nausea and diaphoresis prior to loss of consciousness due to hypotension and/or bradycardia. Usually the syncopal episode last less than a minute but accompanying nausea, diaphoresis, and pallor can last longer. Many patients do not have a prodrome sufficiently long upon which to act, and therefore are unable to use preventive techniques such as counterpressure maneuvers or sitting/lying down to avoid or minimize a full episode. Unlike patients with cardiac or neurologic cause for syncope, patients with vasovagal syncope have no increased risk of cardiovascular morbidity or mortality (Soteriades et al., 2002). Hence in patients with vasovagal syncope preventing injury and maintaining a good quality of life are the primary goals for management(Kuriachan & Sheldon, 2008).
Bradycardia has long been recognized as a component of vasovagal syncope(Sharpey-Schafer, 1956). In recent years, bradycardia was seen during tilt table test studies in patients with vasovagal syncope during the induced episodes(Mosqueda-Garcia et al., 1997). Bradycardic problems have also been detected by pacemaker and implantable loop recorders during clinic episodes of vasovagal syncope(Krahn, Klein, & Yee, 1997). This suggested that pacing could prevent vasovagal syncope by treating the bradycardia component. This was initially looked at in patients with tilt table induced syncope associated with bradycardia(Fitzpatrick, Theodorakis, Ahmed, Williams, & Sutton, 1991). These patients underwent repeat tilt table test with temporary pacing. This prevented syncope in over half the patients although they still experienced vasovagal symptoms and presyncope. The results of this study should also be interpreted with caution since repeated tilt table testing can have a training effect and may reduce syncopal episodes(Reybrouck, Heidbuchel, Van De Werf, & Ector, 2002). Also the hemodynamic changes seen on tilt table induced syncopal episodes may not correlate with clinical episodes(Menozzi et al., 1993).
Initial observational studies seemed to show benefit with pacing as a treatment for vasovagal syncope(Sheldon, Koshman, Wilson, Kieser, & Rose, 1998; Petersen et al., 1994; Benditt et al., 1997). These initial studies were mainly a sequential design, with no placebo group, and included highly symptomatic patients, who received a pacemaker. Open label studies then followed which also showed impressive results with pacing. The North American Vasovagal Pacemaker Study (VPS) randomized 54 vasovagal syncope patients to a pacemaker or optimal medical treatment(Connolly, Sheldon, Roberts, & Gent, 1999a). Impressive results, as shown in Figure 1, were seen with 19/27 in the medical treatment group and only 6/27 in the pacemaker arm having one or more recurrences of syncope. The Vasovagal Syncope International Study (VASIS) randomized 42 syncope patients with cardioinhibitory responses on tilt table testing to pacemaker or medical therapy(Sutton et al., 2000). Again, an impressive reduction in syncope was seen, with only 5% in the pacemaker group and 61% in the medical therapy having syncope recurrence. Another open label study, Syncope Diagnosis and Treatment Study (SYDAT), randomized 93 syncope patients to a pacemaker or atenolol(Ammirati, Colivicchi, & Santini, 2001). This also showed a significant reduction in syncope with pacing (4.3%) versus atenolol (26%). Hence initial observational and open-label studies suggest a significant reduction in syncope recurrence with pacing with up to 87% relative risk reduction(Sud et al., 2007a; Connolly, Sheldon, Roberts, & Gent, 1999b). Summaries of the observational and randomized open-label pacing studies in vasovagal syncope are shown in Table 1.
|Study (year)||Type of Study||Tilt Testing part of inclusion||Study Arms||Results|
|Sheldon et al. (1998)||Observational||Yes||12 patients with VVS. Rate drop pacing in all patients||No syncope in 50%|
|Peterson et al. (1994)||Observational||Yes||37 patients with VVS. 35 had DDD and 2 had VVI||No syncope in 62%|
|Benditt et al (1997)||Observational||No||31 patients with VVS or CSS. Rate drop pacing in all patients||No syncope in 80%|
|VPS I (1999)||Open-label randomized||Yes||54 patients with VVS randomized to rate drop pacing or no implant||85% relative risk reduction|
|SYDAT (2001)||Open-label randomized||Yes||93 patients with VVS randomized to ppm with rate drop response or to atenolol||83 % reduction of syncope with pacing|
|VASIS (2000)||Open-label randomized||Yes||42 patients with VVS randomized to ppm with hysteresis and 23 with no implant||90% reduction of syncope with pacing|
Various pacemaker settings have been tried in patients with vasovagal syncope. In general dual chamber (AV sequential) pacing is preferred, since both sinus and atrioventricular nodal function can be affected during a vasovagal episode. DDD pacing was compared to VVI and to sensing only (ODO) in 12 children with vasovagal syncope and found both modes of pacing to prevent syncope(McLeod, Wilson, Hewitt, Norrie, & Stephenson, 1999). All 12 were implanted with dual chamber pacemakers. Then programmed to ODO, VVI, and DDD with rate drop response for four month periods. Parents and patients were blinded to the pacemaker mode. Physician analyzing the results were blinded to patient and pacemaker mode. Even though both pacing modes prevented syncope, DDD was better than VVI for reducing presyncopal events.
Rate-changing programming has also been examined including rate hysteresis, rate smoothing, and rate drop response. The goals of these programming strategies are to treat the bradycardia and also to compensate for the hypotensive/vasodepressive response. Rate hysteresis triggers pacing at a higher rate when the intrinsic heart rate falls below a preset rate. Rate smoothing prevents sudden changes in heart rate by pacing when there is an abrupt drop in intrinsic heart rate even in just 1-2 beats. (This is also used in patients with atrial fibrillation.) Rate drop response, the most sophisticated of the three, results in high rate pacing for a few minutes when a drop in native heart rate is detected. This hopes to achieve pacing support that can overcome bradycardia and hypotension. Rate response programming has been used in many syncope studies including VPS and VPS II. One study compared DDD with rate drop response to DDI with rate hysteresis in vasovagal syncope(Ammirati et al., 1998). This study randomized 20 vasovagal syncope patients with cardioinhibitory response during tilt testing to rate drop response or rate hysteresis. During the 17 month follow up, no patients with rate drop response had syncope but 3 of 8 in the rate hysteresis group had recurrence of syncope. Hence rate drop response was found to be more effective. Recent studies have also looked at closed loop stimulation (CLS). In closed loop stimulation variation of intracardiac impedance is tracked every beat, so that contractility changes can be detected in the early phase (prior to changes in heart rate) of a vasovagal episode and dual chamber pacing is activated(Occhetta, Bortnik, Audoglio, & Vassanelli, 2004a), as shown in Figure 2. This early initiation of pacing is believed to not only treat the bradycardic response that may follow but also overcome the transient hypotension. The INVASY trial randomized 55 patients with vasovagal syncope and positive tilt test to a CLS pacemaker or DDI and found CLS to be effective in preventing syncope over two-year follow-up period(Occhetta et al., 2004a). None of the patients had recurrences of syncope while in a CLS mode. However both groups had a reduction in syncope, likely due to a placebo effect. The recently completed, but not published, SCANSYNC study also used CLS pacing, described below. A preceding single blind cross-over study of 23 patients used a microaccelerator-equipped ventricular pace/sense leads (Sorin Biomedica, Saluggia, Italy) with a sensor at the tip that measures peak endocardial acceleration that correlates with measurements of left ventricular contractility(Deharo et al., 2003). This study compared standard DDI pacing to a rate adaptive (DDDR) specialized pacing system with a microaccelerometer in the right ventricular lead to detect myocardial contractivity. Both modalities were found to decrease syncopal episodes; in addition, the contractility-driven DDDR might have an additive benefit to conventional DDI pacing (Deharo et al., 2003).
The great success of the initial studies raised the possibility a placebo effect with implant of a pacemaker for treatment of vasovagal syncope. Hence the first randomized, multicenter, double blinded study was designed and completed. VPS II, in which all 100 patients received pacemakers but were randomized to dual chamber pacing with rate drop sensing or sensing only(Connolly et al., 2003). After six months of follow up, there was no significant benefit with pacing and showed a 40% cumulative risk of syncope in the sensing group and 31% in the pacing group. This was also confirmed in a smaller study that included 29 patients with recurrent tilt-induced vasovagal syncope and one relapse after tilt testing (SYNPACE)(Raviele et al., 2004). In this study, patients all received a pacemaker and then were randomized to pacing or no pacing. Results of the first interim analysis and VPS II stopped this trial prematurely. They were unable to show a benefit with active pacing in preventing syncope.
A recent meta-analysis examined the role of pacing in vasovagal syncope(Sud et al., 2007b). Nine randomized trials were looked at in the meta-analysis, which included open label, single blind, and double blind trials. Interestingly, in contrast to open label trials, blinded trials for pacing in vasovagal syncope do not show a benefit, even in patients with marked cardioinhibitory response on tilt table testing(Sud et al., 2007a). Therefore, a cardioinhibitory response on tilt table testing probably is neither an appropriate surrogate marker for pacing studies, nor can it be used to predict patients who might respond to pacing.. The authors of the meta-analysis described that the benefits seen in open label, unblinded trials as being due to an expectation effect, by both patients and physicians. The authors of this meta-analysis synthesized a unique comparison between “inactive” pacing and no treatment and found that the expectation response alone reduces the odds of syncope by 84% (Figure 3).
|Study (year)||Number of Patients||Type||Tilt Testing part of inclusion||Study Arms||Results|
|VPS II (2003)||100||Double blind randomized||No||Rate drop pacing vs ODO||Pacing did not reduce risk of syncope|
|SYNPACE (2004)||29||Double blind randomized||Yes||DDD rate drop vs ODO||Pacing did not reduce risk of syncope|
|Deharo et al. (2003)||23||Single blind randomized crossover||No||Contractility driven DDDR vs DDI||Both reduced syncope. Contractility driven may be better than DDI|
|INVASY (2004)||50||Single blind randomized crossover||Yes||DDD-CLS compared to DDI||Both reduced syncope. CLS pacing seems to be better than DDI.|
|Mcleod et al. (1999)||12||Double blind randomized||No||DDD vs VVI vs ODO||Pacing prevented syncope. DDD further reduced presyncope.|
The placebo effect can be powerful and may be due to expectation effects of patients and health care providers, conditioning effects in patients, along with biases in patient assessment and reporting(Olshansky, 2007). Patients who receive pacemakers, due to the expense and invasive nature of the treatment, may be more willing to consider it as being a beneficial treatment for their problems. Healthcare workers who are involved in the care of these patients may not be conscious of biases they are exhibiting in assessment and reporting, and may also apparently observe a benefit from an ineffective intervention. Conversely those patients who did not receive pacemakers in studies may be disappointed and more inclined to report symptoms. Similar situations have also been encountered in the past with hypertrophic cardiomyopathy, where pacing was initially thought to improve functional status in open label studies(Nishimura et al., 1997). Similarly, atrial pacing was first reported to reduce atrial fibrillation, stroke, and death in patients with pacemakers(Gillis et al., 1999; Connolly et al., 2000). However, randomized, controlled studies did not show the benefits that were seen in the open label studies in any of these situations(Gillis et al., 1999; Connolly et al., 2000; Nishimura et al., 1997). Hence interpretation of studies in pacing that are not randomized, double blind, placebo-controlled should be done with caution since there may be important placebo effects. The vasodepressor and cardioinhibitory components may vary in each patient with different episodes and 50% to 83% of syncopal episodes may not have a cardioinhibitory component(Sheldon & Connolly, 2003). This may also explain why pacing does not seem to be of benefit in vasovagal syncope. Pacing alone may not be enough to overcome vasodepression.
Although the two blinded randomized trials are small (VPS II and SYNPACE), it seems pacing may not benefit most patients with vasovagal syncope. The ISSUE 2 study reported 392 patients with recurrent syncope and an implantable loop recorder (ILR)(Brignole et al., 2006). Specific treatment was then given to 53 patients based on the monitoring findings, of whom 47 received a pacemaker for asystole and 6 received anti-tachycardia treatments. A marked decrease in syncopal episodes was noted in the group that received specific treatment. In the 53 patients receiving specific treatment, the 1-year syncope recurrence rate was 10% compared to 41% in the patients without specific treatment. However the study is limited by lack of blinding and having only a minority of patients receiving specific treatment. To overcome the limitation of ISSUE 2, the ISSUE 3 study was designed (Brignole, 2007). Patients found to have asystolic pauses associated with syncope on ILR monitoring were randomized to pacemaker On or Off. This is a multicenter, randomized, placebo-controlled, prospective study of patients with a documented pause during syncope on an implantable loop recorder and then randomized to a pacemaker with pacing or only sensing. ISSUE 3 has finished recruitment and is now in the follow-up phase. The results of this study will help to clarify whether pacing may be of benefit in vasovagal syncope patients with prolonged asystolic pauses. As mentioned previously, initial studies also suggest that using a closed loop pacing (CLS) that detects contractility may be able to detect a neurocardiogenic episode early and provide pacing support better than a rate drop system(Kanjwal, Karabin, Kanjwal, & Grubb, 2010; Occhetta, Bortnik, & Vassanelli, 2003; Occhetta, Bortnik, Audoglio, & Vassanelli, 2004b). A randomized, prospective, double blind, cross over study (SCANSYNC) compared active (CLS pacing) to passive (VVI 30) pacing in patients with recurrent vasovagal syncope has been completed and is awaiting publication.
Other treatments for vasovagal syncope have also had similar findings with open label and observational studies showing benefit but double blind, randomized studies showing minimal benefit or no difference from placebo(Kuriachan, Sheldon, & Platonov, 2008). In patients with an identifiable prodrome there may be some benefit to using physical counterpressure maneuvers (PCM) which are safe and cost free(van et al., 2006). The maneuvers used are usually leg crossing with tensing of abdominal, buttock, and lower extremity muscles and/or gripping hands while abducting both arms. These maneuvers should be tried as first line treatments in patients with vasovagal syncope and an identifiable prodrome. Ensuring adequate volume repletion is important with salt and fluid intake. Various medications have also been studied, including beta-blockers, selective serotonin re-uptake inhibitors (SSRI), Fludrocortisone, and Midodrine. In general, no clear benefit has thus far been seen from studies with beta-blockers, SSRIs, and fludrocortisone(Kuriachan & Sheldon, 2008). The POST II study is comparing fludrocortisone to placebo in a randomized, double blind fashion and is in the follow-up phase (Raj, Rose, Ritchie, & Sheldon, 2006). Midodrine, a peripherally acting alpha-agonist, does seem to have some benefit in adults and children. Frequent dosing and some side effects, such as supine hypertension, may limits its use(Kuriachan et al., 2008). POST IV will be a double blind, randomized, placebo controlled study comparing midodrine to placebo in patients with vasovagal syncope.
The initial management approach to a patient with vasovagal syncope should include education about the condition, reassurance, and dietary intake (particularly salt and fluid). PCM should be taught to patients with a prodrome. If they still have frequent recurrent symptoms then medications attempts should be made. Pacing should be reserved as a last resort and ideally in patients documented with asystole during their syncopal episodes. A frank and open discussion should be held with the patient about the limited benefit that has been seen in studies for medications and pacing. Refer to Figure 4 for management approach for vasovagal syncope.
Carotid sinus hypersensitivity and association with syncope have been known for many years. Carotid sinus hypersensitivity (CSH) is defined as a fall in systolic BP > 50mmHg and/or asystolic pause > 3 seconds with carotid sinus massage. Carotid sinus syndrome is when CSH is associated with spontaneous syncope that can be reproduced with carotid sinus massage(CSM). Carotid sinus syncope tends to happen in elderly men and the prevalence increases with cardiovascular, cerebrovascular, and neurodegenerative disease(Claesson, Kristensson, Edvardsson, & Wahrborg, 2007). A fall from syncope can result in significant injuries given the older age of this patient population. Although there is limited evidence, carotid sinus syncope has been believed to occur in the context head turning movements that may cause pressure on the carotid, such as shoulder checking in a car with shoulder seat belt putting pressure or wearing a tight collar.
It is important to differentiate carotid sinus hypersensitivity from carotid sinus syndrome. A positive carotid sinus massage was noted in 32% of patients having an angiogram who had no history of carotid sinus syncope(Brown, Maloney, Smith, Haritzler, & Ilstrup, 1980). Asymptomatic carotid sinus hypersensitivity may be common in the elderly. Carotid sinus reflex helps with hemodynamic regulation. The vagal efferent signals increases cardiac vagal input resulting in lowering heart rate and peripheral vasodilation lowering blood pressure(LOWN & LEVINE, 1961). Hence an abnormal reflex can cause significant changes in blood pressure and heart rate which decreases brain perfusion and results in syncope.
Various protocols have been used for carotid sinus massage (Brignole et al., 2001). In one method, the carotid artery is firmly massaged at the anterior margin of the sternocleidmastoid at the cricoids cartilage level for up to 5 seconds, while the patient is in a supine position. If the first side does not yield a positive result then CSM is performed on the other side. Asystolic pause > 3 seconds (sinus pause or at times due to AV block), fall in BP > 50mmHg, and development of symptoms are necessary for a truly positive test. Abnormal responses can also be seen in patients with a history of spontaneous syncope. Some protocols use longer duration of massage to reproduce spontaneous symptoms, as well as both supine and upright positions (ensure patient safety in upright position). Heart rate changes can be readily seen on cardiac monitoring but a blood pressure drop is difficult to document without invasive monitoring (not usually practical) or noninvasive continuous digital plethysmography. CSM is contraindicated in patients with carotid bruits or history of prior stroke/TIA, due to concerns that the CSM may result in carotid plaque disruption and embolization resulting in a cerebrovascular event. Studies have looked at the safety of CSM, totaling over 5000 patients and found complication rates in the 0.1 – 0.2% range, of which most were transient neurological symptoms and full recovery was made except in two patients(Munro et al., 1994; Davies & Kenny, 1998).
One of the first studies in carotid sinus syncope reported 70 patients with CSH and syncope, and found pacing to be very effective(Morley et al., 1982a). Subsequently a second study assessed 56 consecutive patients with CSH and syncope who had received no treatment (13 patients), anticholinergic medications (20), and pacemaker implant (23). In this study, pacing was effective in preventing syncope but a high rate of spontaneous remission was also observed(Sugrue et al., 1986). Another study with 21 patients, in which 13 received pacemakers, found only minimal benefit with pacing(Huang, Ezri, Hauser, & Denes, 1988). However, none of the patients with pacemakers had recurrences of syncope and only one patient had recurrence in the no pacemaker group of eight patients, demonstrating a very low recurrence rate even without receiving treatment. Other observational studies also found benefits from pacing and are listed in Table 3(Brignole et al., 1991; Brignole, Menozzi, Lolli, Sartore, & Barra, 1988).Hence some benefit was observed with pacing in CSH and syncope in the initial studies, but there were high rates of spontaneous remission.
Since many elderly patients who have syncope may not remember the details of the event and prodrome, they may present with a non-accidental fall. Hence it was thought that in many elderly patients, carotid sinus syncope might be responsible for non-accidental falls. This was first examined in the SAFE-PACE trial(Kenny et al., 2001). This open-label study included 175 consecutive patients over the age of 50 with non-accidental falls attending an accident and emergency facility. Those with carotid sinus hypersensitivity were randomized to rate drop dual chamber pacemaker or standard treatment. Paced patients were significantly less likely to fall (odds ratio 0.42) and reduced injurious event by 70%. SAFE-PACE 2 was a double blind, randomized study done to assess this(Daniel, Steen, Seifer, & Kenny, 2010). 141 patients with unexplained falls and cardioinhibitory carotid sinus hypersensitivity were randomized to a rate responsive pacemaker or implantable loop recorder. No significant reduction was seen in the pacemaker group, but this small sample size led to an underpowered study. Again, due to concerns of the open-label nature of the initial SAFE-PACE, a randomized study was conducted in which 25 patients received pacemakers but was randomized to pacemaker On (DDD) or Off (ODO)(Parry, Steen, Bexton, Tynan, & Kenny, 2009). This was a double blind study with a cross over design. There was a mean of 3.48 falls in the ODO mode and 4.04 in the DDD mode. Survival analysis showed no significant differences in time to first fall between the two groups (Figure 5). Hence no benefit was seen with pacing in this group for fall reduction. Further supporting the placebo effect in this study was the fall reduction that was seen in both groups, pacemaker On or Off, in the first six months after implant. However, this study was underpowered and should be interpreted with caution. Hence the initial impressive benefits seen in SAFE-PACE may be due to a placebo effect similar to the open-label vasovagal pacing studies.
|Study (year)||Number of Patients||Methodology||Study Arms||Results|
|Sugrue et al. (1986)||56||Observational||13 no treatment 23 pacemaker 20 anticholinergics||Pacing was effective but high rate of spontaneous remission|
|Morley et al. (1982)||70||Observational||54 patients VVI 13 patients DVI 18 patients DDD||89% asymptomatic with pacing|
|Huang et al. (1988 )||21||Observational||13 with pacemaker 8 with no implant||Pacing found to be beneficial. However only one patient had recurrence (in no pacer group)|
|Brignole et al. (1991)||60||Observational Crossover||26 with DDD 34 with VVI||DDD found to have less symptoms overall|
|Brignole et al.(1988)||35||Observational||19 no implant 11 with VVI 5 with DDD||Pacing prevented syncope recurrence|
|SAFEPACE 1 (2001)||175||Open label||87 with pacemaker 88 no implant||Pacing reduced falls and minimal reduction of syncope|
|SAFEPACE 2 (2010)||141||Double blind||71 with pacemaker 70 with loop recorder||No significant reduction in falls seen|
|Parry et al. (2009)||25||Double blind Crossover||25 DDD and crossover to ODO||Pacing had no effect of falls|
Although only a few small studies have shown benefit, pacing has generally been felt to be beneficial in this condition, especially in elderly patients with a predominantly cardioinhibitory response to CSM and present with symptoms suggestive of carotid sinus syncope(Brignole, Menozzi, Lolli, Bottoni, & Gaggioli, 1992; Morley et al., 1982b; Claesson et al., 2007; Moya et al., 2009). Management should also include volume repletion and recommendations on avoiding situations that may cause syncope, such as tight collars and ties. Volume expanders and vasopressors may also be helpful but usually are limited due to problems with heart failure and hypertension that is common in the elderly population.
Initial steps in the management of vasovagal syncope should include education about the diagnosis and reassurance. Patients should be instructed on liberal intake of salt and fluid. Counterpressure maneuvers should be taught to patients with a prodrome. If they still have frequent recurrent symptoms, then medications attempts should be made. Pacing should be reserved as a last resort and ideally in patients documented with asystole during their syncopal episodes. For patients with carotid sinus syncope, pacing should be considered. Additional management should also include volume repletion and recommendations on avoiding situations that may cause syncope.
1926total chapter downloads
Login to your personal dashboard for more detailed statistics on your publications.Access personal reporting
Edited by Oliver Vonend
By Sebastian A. Potthoff, Lars-Christian Rump and Oliver Vonend
Edited by Mithilesh M Das
By Dieter Hayn, Hannes Kumpusch, Rene Labenbacher, Robert Modre-Osprian and Günter Schreier
We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.More about us